Chimagen Biosciences
Latest round
- Series B
Last raised
- Nov 2024
Total raised
- Undisclosed
Investors
- 2
About Chimagen Biosciences
Founded in 2016 in Shanghai, China, Chimagen Biosciences focuses on advancing multi-functional monoclonal antibodies for cancer treatments. The company has executed 5 deals, with their most recent deal occurring on November 1, 2024.Chimagen Biosciences specializes in developing a new class of multi-functional monoclonal antibodies, with a primary focus on innovative therapies for oncology, particularly colorectal cancer. Their flagship product, CMG12, is a trispecific antibody designed to activate the immune system to target and eliminate cancer cells, addressing significant unmet medical needs in cancer treatment. The company's expertise spans from early discovery through clinical studies, partnering with leading research organizations and professionals in the immune-oncology sector to enhance the efficacy of their therapeutic offerings.Chimagen Biosciences generates revenue through strategic partnerships and collaborations with research institutions and healthcare providers, focusing on B2B transactions. Their business model includes the potential for licensing agreements and joint ventures, allowing for shared development of their innovative monoclonal antibody products. The firm is committed to delivering effective cancer treatments, and its revenue structure is built around the commercialization of its flagship products, including CMG12, through partnerships with pharmaceutical companies and clinical research organizations. The company is also actively designing new products and aims to enter additional markets, particularly regions with robust oncology research initiatives, by mid-2025.
Who invested in Chimagen Biosciences
2 investors across 1 round
See all investors in Chimagen Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Nov 1, 2024
Amount
Undisclosed
Investors
Questions about Chimagen Biosciences
Who invested in Chimagen Biosciences?
Chimagen Biosciences has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Chimagen Biosciences raised?
Chimagen Biosciences has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Chimagen Biosciences last raise money?
Chimagen Biosciences's most recent round on record is a Series B, in Nov 2024.
What does Chimagen Biosciences do?
Founded in 2016 in Shanghai, China, Chimagen Biosciences focuses on advancing multi-functional monoclonal antibodies for cancer treatments.
Where is Chimagen Biosciences headquartered?
Chimagen Biosciences is headquartered in Shanghai, China.
Which VCs invest in companies like Chimagen Biosciences?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Chimagen Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Chimagen Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.